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SUMMARY 
 
 
Due to the long-term effects of acute and chronic lung diseases of infancy and childhood 
research exploring the pathomechanism and treatment of paediatric pulmonary diseases is a 
priority. A large number of chronic lung diseases, e.g. bronchopulmonary dysplasia or asthma 
bronchiale, is associated with alveolar and bronchial inflammation. Proteolytic changes play 
a significant role in the damage to the alveolocapillary barrier. The role of proteolytic 
pathways in the epithelial damage has been investigated in the present study in order to find 
potential protective mechanisms which could reduce the injury caused by proinflammatory 
cytokines.  
 
Tumour necrosis factor-α, interleukin-1β, interleukin-2, interferon-γ, and bacterial 
lipopolysaccharide were able to induce significant increase in plasminogen activator activity 
in A549 human alveolar epithelial cells. Tumour necrosis factor-α had time- and dose-
dependent effects both on urokinase and tissue-type plasminogen activator induction. This 
cytokine could also significantly activate matrix metalloproteinase 2 in A549 cells and 
increased migration potential of wounded epithelial cells. All of these inductions could be 
inhibited by dexamethasone and an inhibitor of Rho-kinase. Tumour necrosis factor-α 
treatment also caused damage to the integrity of epithelial cellular barrier, it led to 
relocalisation of the tight junction transmembrane protein occludin, and to a dose-dependent 
decrease in the expression of adherens junction protein β-catenin. 
 
The present study indicates that cytokines promote fibrinolysis in alveolar epithelium and 
contribute to pathogenesis and repair of lung injury. Tumour necrosis factor-α is responsible 
for the induction of proteolytic activity and the injury of alveolocapillary barrier, while 
glucocorticoids and Rho-kinase inhibitors may have potential role in future therapeutic 
approaches. Data obtained on in vitro models may contribute to detection of the signal 
transduction pathways regulating epithelial proteolytic activity in response to inflammatory 
stimuli and to identification of potential therapeutic target molecules. 
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ABBREVIATIONS 
 
AF6, acute lymphoblastic leukemia 1 fusion partner from chromosome 6 
AHR, airway hyperresponsiveness 
ALI, acute lung injury 
AP-1, activator protein-1  
BAL, bronchoalveolar lavage 
BPD, bronchopulmonary dysplasia;  
CASK, calcium/calmodulin-dependent serine protein kinase 
CECs, cerebral endothelial cells 
CLD, chronic lung disease 
DMEM, Dulbecco’s modified Eagle’s medium 
DXM, dexamethasone 
ECM, extracellular matrix 
ERK 1/2, extracellular signal-regulated kinase 1/2 
FCS, foetal calf serum 
GTPase, guanosine triphosphatase 
IFN-γ, interferon γ 
IgG, immunoglobulin G 
IL, interleukin 
IL-n, interleukin n 
LPS, lipopolysaccharide 
MMP, matrix metalloproteinase 
MMPn, matrix metalloproteinase n 
NF-κB, nuclear factor-κB  
PA, plasminogen activator 
PAI, plasminogen activator inhibitor 
PAI-n, plasminogen activator inhibitor-n 
PAR, protease-activated receptor 
PBS, phosphate-buffered saline 
PDTC, pyrrolidine dithiocarbamate 
PKC, protein kinase C 
pro-uPA, pro-urokinase-type plasminogen activator 
RDS, respiratory distress syndrome 
SDS-PAGE, sodium dodecyl sulfate polyacryl-amide gel electrophoresis 
SEM, standard error of mean 
SOD, superoxide dismutase 
TGF-β, transforming growth factor-β 
TIMP, tissue inhibitor of metalloproteinases 
TIMP-n, tissue inhibitor-n of metalloproteinases 
TJ, tight junction 
TNF-α, tumour necrosis factor-α 
tPA, tissue-type plasminogen activator 
uPA, urokinase-type plasminogen activator 
uPAR, urokinase-type plasminogen activator receptor 
ZO, zonula occludens 
ZO-n, zonula occludens-n 
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1. INTRODUCTION 
 
Respiratory illnesses are the major cause of morbidity and mortality in childhood. Asthma, a 
chronic inflammatory disorder characterized by episodic and reversible airflow obstruction 
and airway hyperresponsiveness (AHR), has a prevalence of 8.5% in childhood and causes 
significant mortality. In addition to genetic factors, pre- and postnatal environmental 
exposures, acute and chronic lung diseases of infancy and childhood have long-term effects 
on lung structure and function which persist and adversely affect lung function and 
respiratory health into adulthood. The research in paediatric pulmonary diseases is a priority.  
 
1.1. Pulmonary Inflammations 
Acute inflammation in the respiratory tract is an immediate defense reaction to inhaled 
allergens, pathogens or noxious agents which is accompanied by increased mucus secretion. 
The acute response is followed by a repair process that restores the tissue back to normal 
involving proliferation of damaged epithelial cells and fibrosis. The repair process may 
become chronic in response to continued inflammation, resulting in remodelling, i.e. 
structural changes in the airways.  
Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (RDS), 
are characterized by an acute inflammatory process in the air spaces and lung parenchyma. 
The loss of barrier function of alveolar epithelial and pulmonary capillary endothelial cells 
results in respiratory failure in critically ill patients. Pro- and anti-inflammatory cytokines and 
chemokines play a major role in mediating, amplifying, and perpetuating inflammatory-
induced lung injury from sepsis, pneumonia, aspiration, and shock.  
Chronic inflammation in the airways may persist for many years, sometimes even in the 
absence of the causal mechanisms. The molecular and cellular mechanism involves both 
long-lived immunologic memory cells and structural cells in the airways. The structural 
changes may result in irreversible narrowing of the airways with the reduction in air flow. 
These changes include fibrosis, increased amount of airway smooth muscle, and increased 
number of blood vessels. 
Chronic lung disease (CLD) of infancy most commonly occurs in low birth weight preterm 
infants treated for RDS, but any disorder that results in ALI or requires treatment with 
positive-pressure mechanical ventilation and high O2 concentration predisposes to this 
disease. The lung injury in bronchopulmonary dysplasia (BPD) includes re-epithelialization 
of denuded alveoli followed by the increased presence of fibroblasts and major areas of 
fibrosis. Elevated concentrations of cytokines, such as interleukins (ILs) IL-1β, IL-6, IL-8, 
and tumour necrosis factor-α (TNF-α) were observed in tracheal aspirates and serum of 
infants with RDS and contributed to the development of BPD.  
Chronic inflammatory processes of the airways are important elements of several CLDs. 
Asthma is characterized by episodic wheezing, lung inflammation, and progressive 
irreversible airway dysfunction in some patients. Histological hallmarks of asthma include 
homing of T-helper 2 inflammatory cells into lung parenchyma, eosinophilia, and increased 
mucous cell metaplasia. Epithelial cell damage and infiltration of the bronchial wall by 
inflammatory cells can be observed in the airways of bronchial asthma patients. Other 
irreversible changes include increased deposition of extracellular matrix (ECM) proteins in 
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the bronchial wall, hyperplasia and hypertrophy of smooth muscle cells and an increased 
number of blood vessels. Allergen challenge and clinical asthma are associated with synthesis 
and release of pro-inflammatory cytokines, such as TNF-α, IL-1, or IL-13. These mediators 
can be found in bronchoalveolar lavage (BAL) fluid in status asthmaticus. 
 
1.2. Inflammatory and Structural Cells in the Airway Inflammations 
Inflammation is characterised by an infiltration with inflammatory cells depending on the 
type of process. Mast cells, macrophages, dendritic cells, eosinophil, neutrophil and basophil 
granulocytes, T- and B-lymphocytes, and platelets are involved in asthma. Structural cells of 
the airways, such as epithelial cells, smooth muscle cells, endothelial cells, and fibroblasts 
may also be an important source of inflammatory mediators. Structural cells outnumber 
inflammatory cells in the airways, therefore they may become the major source of mediators.  
Bronchial epithelial cells represent an essential component of the innate immune system. 
They are in direct contact with inhaled materials, including pollutants, allergens, proteases, 
microbes, and other factors that are relevant to the development of human asthma. Airway 
epithelial cells have a key role in translating inhaled environmental signals into an 
inflammatory response. Epithelial cells express various pattern recognition receptors 
including Toll-like receptors and protease-activated receptors (PARs), which recognize 
microbial motifs and allergens. The activation of epithelial cells through these diverse 
pathways results in the production of chemokines and cytokines, which may attract 
inflammatory dendritic cells to the lung and induce the maturation of these cells. 
 
1.3. Cytokines and Other Inflammatory Mediators in the Lung 
Inflammatory mediators have been implicated in the pathogenesis of asthma and CLDs. Their 
effects on the airways could account for the pathology of allergic diseases. Mediators such as 
histamine, prostaglandins, leukotrienes and kinins contract airway smooth muscle, increase 
microvascular leakage, increase airway mucus secretion, and attract other inflammatory cells. 
These vasoactive mediators are important in acute and subacute inflammatory responses and 
asthma exacerbations, while cytokines and chemokines play a role in maintaining chronic 
inflammation. Many inflammatory (macrophages, mast cells, eosinophils, lymphocytes) and 
structural (epithelial cells, airway smooth muscle cells, endothelial cells) cells can synthesise 
and release these proteins. TNF-α axis is up-regulated in patients with refractory asthma, as 
evidenced by the increased expression of membrane-bound TNF-α, TNF receptor 1, and 
TNF-α converting enzyme by monocytes. TNF-α have multiple effects in asthmatic airways; 
it induces adhesion, migration, and activation of inflammatory cells through the epithelial and 
endothelial barriers. Effective anti-TNF therapy supports the view that TNF-α contributes to 
the pathogenesis of asthma. Both TNF-α and IL-1β activate pro-inflammatory transcription 
factors, nuclear factor-κB (NF-κB) and activator protein-1 (AP-1), which switch on many 
inflammatory genes in the asthmatic airways. Other cytokines, such as interferon-γ (IFN-γ), 
IL-10, IL-12, and IL-18, play an inhibitory role in the allergic inflammatory process. During 
allergic inflammation activated inflammatory cells, e.g. macrophages and eosinophils, 
produce reactive oxygen species. Increased oxidative stress is related to disease severity. 
Oxidative stress may be detrimental in asthma through the reaction of superoxide anions with 
nitric oxide to form the reactive radical peroxynitrite, that may modify several target proteins. 
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1.4. Regulation of Proteolysis in the Lung 
Proteolytic enzymes may also cause damage to the lung during inflammatory process. 
Extracellular endogenous proteases are released by circulating inflammatory cells and 
resident lung cells, while exogenous proteases derive from mites and molds. The majority of 
endogenous proteases that cause lung injury is generated by neutrophils, although 
macrophages, T-lymphocytes, eosinophils, basophils, mast cells, type II alveolar epithelial 
cells or fibroblasts also release proteases in smaller quantities. Proteases are important in 
normal growth and development of the lung and in lung host defense. They can injure cells 
directly, degrade ECM components and break down extracellular and cell surface 
macromolecules under pathological circumstances. Proteases can react with airway receptors 
to generate leukocyte infiltration and to amplify the response to allergens. They contract 
bronchial smooth muscle and cause it to proliferate. Proteases can promote maturation, 
proliferation, and collagen production of fibroblast precursors and mature fibroblasts. 
Proteolytic enzymes can also degranulate eosinophils and mast cells. 
Protease classification is based on the essential amino acid at the active site. Serine-
proteinases include neutrophil elastase, cathepsin G, proteinase-3, granzymes, chymase, and 
plasminogen activators (PAs). Cathepsin L and B are cysteine-proteinases, cathepsin D is an 
aspartic-protease. Proteases containing metal ions are metalloenzymes, such as matrix 
metalloproteinases (MMPs). Proteases act through PARs, 7-transmembrane proteins coupled 
to G proteins. Stimulation leads to increased intracellular Ca2+ level and gene transcription. In 
alveolar epithelial cells it opens tight intercellular junctions, causes desquamation, and 
produces cytokines, chemokines, and growth factors. Lung antiproteases include α1-
antitrypsin, α2-macroglobulin, secretory leucoprotease inhibitor, tissue inhibitor of metallo-
proteases (TIMPs), plasminogen activator inhibitor (PAI)-1 and -2, and α1-antichymotrypsin.  
 
1.4.1. The plasmin system in the lung 
Components of the plasmin system, such as tissue-type PA (tPA), urokinase-type PA (uPA), 
and inhibitors PAI-1 and PAI-2 are synthesised by airway cells. Endothelial cells, fibroblasts, 
epithelial cells, mast cells, monocytes/macrophages and smooth muscle cells are responsible 
for production of PAs. Plasmin system inhibitors can be also synthesised by platelets,  
neutrophils, and fibroblasts. Inflammatory mediators affect the expression of PAs and PAIs, 
and the plasmin system, in turn, can also actively influence the production of mediators and 
growth factors, extending pathological structural changes in the airway. 
Plasminogen is converted into plasmin, its active form, by uPA or tPA. uPA is secreted as an 
inactive precursor form (pro-uPA) that binds with high affinity to a specific cell surface 
glycosylphosphatidylinositol-anchored receptor named uPAR. The binding of pro-uPA to 
uPAR activates uPA and enhances the generation of plasmin at the cell surface, promoting 
matrix degradation, the activation of MMPs, and growth factors. PAI-1 is the physiological 
inhibitor of  PAs, while local activity of plasmin remains also under the control of α2-
antiplasmin and α2-macroglobulin. However, inflammatory mediators including IL-1, IL-2, 
IL-4, IL-6, TNF-α, IFN-γ, macrophage colony stimulating factor, transforming growth factor-
β (TGF-β), and tryptase, may also affect the expression of plasmin system components. 
The plasmin system also influences cellular functions without involving proteolytic activity. 
Plasmin may enhance inflammation by inducing neutrophil aggregation, platelet 
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degranulation, and the release of arachidonic acid derivatives. uPAR mediates cell attachment 
and movement, this process remains under the influence of uPA and PAI-1. The fibrinolytic 
system prevents fibrin deposition in the alveolar compartment of normal lung. Decreased 
alveolar fibrinolysis due to altered expression of components of fibrinolytic system takes a 
part in acute lung injury and subsequent fibrosis. The uPA/plasmin system plays a major role 
in airway remodelling in asthma. The changes in the balance of procoagulant and fibrinolytic 
activities also contribute to lung fibrosis in acute RDS and pneumonia. 
Plasmin can degrade most of the protein components of ECM, either by direct removal of 
glycoproteins or by activation of MMPs. It converts inactive MMPs to active forms, which 
are responsible for ECM proteolysis, and prevents neutralisation of MMP by blocking 
inhibitors TIMPs. The action of MMPs is blocked by PAI-1 and serine protease inhibitors. 
 
1.4.2. Matrix metalloproteinases in lung inflammations 
The MMP family consists of approximately 25 zinc-dependent endopeptidases that are 
involved in the remodelling of ECM components. The MMPs share three common domains, 
namely the pro-peptide, the catalytic domain and the haemopexin-like C-terminal domain. 
There are 4 major MMP groups: collagenases, gelatinases, stromelysins, and membrane-type 
MMPs. The collagenases (MMP1, MMP8, MMP13, MMP18) are the only known 
mammalian enzymes capable of degrading triple-helical fibrillar collagens, the major 
components of bone and cartilage. The main substrates of the gelatinases (MMP2, MMP9) 
are type IV collagen and gelatin, and these enzymes also have an additional domain inserted 
into the catalytic domain. The stromelysins (MMP3, MMP10, MMP11) are able to cleave 
ECM proteins, but not the triple-helical fibrillar collagens. The biological processes involving 
MMPs depend on the balance between proteinases and their natural inhibitors. MMPs are 
inhibited by specific endogenous tissue inhibitors, such as TIMP-1, TIMP-2, TIMP-3, and 
TIMP-4. Plasmin prevents neutralisation of MMP by blocking TIMPs. The action of MMPs 
is also inhibited by PAI-1 and other serine protease inhibitors.  
MMPs play a role in many physiological processes, such as embryo implantation, bone 
remodelling, or organogenesis, and in pathological conditions, e.g. tissue reorganization, 
wound healing, or invasion of cancer cells. The known targets of MMPs in the lung are ECM 
molecules, growth factors, chemokines, proteinases, or adhesion molecules.  
MMPs also play a role in the pathogenesis of CLD of prematurity. Increased amounts of 
MMP2, and a higher ratio of MMP9 to TIMP1 have correlated with poor outcome in infants 
with BPD. The interactions between the surfactant proteins and MMPs and TIMPs play an 
important role in the lung maturation process in infants. Expression of several MMPs has also 
been associated with asthma. Increases in MMP1, MMP2, MMP3, MMP8, and MMP9 levels 
have been found in sputum and BAL from patients with asthma.  
 
1.5. Alveolocapillary Barrier in Pulmonary Epithelial Cells 
Barrier function is an important characteristics of the airway epithelium. Tight junctions (TJ), 
specialized structures between adjacent cells, are responsible for the establishment and 
maintenance of a milieu in the alveolar space. TJs are formed by a complex of integral 
membrane proteins and peripheral membrane proteins that interact with the cytoskeleton. 
Integral membrane proteins involved in TJ formation include occludin and members of 
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claudin family. Zonula occludens (ZO)-1 protein has strong interaction with transmembrane 
proteins occludin and claudins, as well as cytoplasmic proteins including ZO-2, ZO-3, actin, 
AF6, or cingulin. There are more than 20 different claudins and alveolar epithelial cells 
simultaneously express six or more claudin isoforms with different paracellular permeability 
characteristics. Adherens junctions are protein complexes that occur at cell-cell junctions 
more basal than TJs and their cytoplasmic face is linked to the actin cytoskeleton. They 
appear as bands encircling the cell (zonula adherens) or as spots of attachment to the ECM 
(adhesion plaques). TJs serve both as a fence differentiating the plasma membrane into apical 
and basolateral domain and as a barrier limiting the passive diffusion of solutes across the 
paracellular pathway. Junctional complexes at cell-cell contact sites also regulate solute flow 
across cell monolayers (through TJs) and from one cell to another (through gap junctions).  
Disruption of the paracellular alveolar permeability barrier is a significant pathological 
consequence of ALI. Chronic inflammation is often associated with increased proteolytic 
activity which contributes to the pathogenesis of asthma through the migration of 
inflammatory cells, matrix deposition and degradation. Loss of epithelial barrier function as a 
consequence of proteases associated with allergens or environmental pollutants results in the 
enhanced access of antigen to dendritic cells. A better understanding of how alveolar 
epithelial cell polarity develops and is maintained, as well as how cell polarity is 
reestablished after injury, is likely to be important for understanding lung injury and repair. 
 
 
2. AIMS 
 
The role of proteolytic pathways in the epithelial damage has been investigated in order to 
find potential protective mechanisms which could reduce the epithelial damage to 
inflammatory cytokines. The specific objectives of the present study were: 
• To investigate the effects of TNF-α and other inflammatory mediators including 
interleukins, interferon, and bacterial lipopolysaccharide (LPS) on the PA activity in 
human alveolar epithelial cells 
• To reveal signal transduction pathways regulating epithelial proteolytic activity in 
response to inflammatory stimuli 
• To investigate MMP activity in epithelial and endothelial cells and reveal TNF-α 
induced regulation 
• To determine TNF-α induced changes in the migration potential of alveolar epithelial 
cells 
• To check possible mechanisms of TNF-α induced damage to the barrier integrity of 
epithelial monolayers 
 
 
3. MATERIALS AND METHODS 
 
3.1. Materials 
Dulbecco’s modified Eagle’s medium (DMEM), E. coli LPS, cytokines (TNF-α, IL-1β, IL-2, 
IL-6, IFN-γ), amiloride, colorimetric substrate (D-Val-Leu-Lys-p-nitroanilide), and other fine 
chemicals were obtained from Sigma (St. Louis, MO, USA),  Plasminogen was purchased 
from Roche (Mannheim, Germany); Y27632 and PP-1 were from Tocris (Avonmouth, UK). 
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3.2. Cell Culture 
Human alveolar epithelial A549 cell line, which retains features of type 2 alveolar epithelial 
cells, was cultured in DMEM containing 10% heat inactivated foetal calf serum (FCS) and 
antibiotics. Confluent epithelial monolayers were washed twice with phosphate-buffered 
saline (PBS) and kept in serum-free DMEM before the experiments. Cells were treated with 
different concentrations of TNF-α (0.1–10.0 ng/ml), LPS (0.5-1 µg/ml), IL-1β (10 ng/ml), IL-
2 (50 U/ml), IL-6 (1 ng/ml), or IFN-γ (1-100 ng/ml) for 3 to 24 hours. Dexamethasone 
(DXM), PP-1, and Y27632 were used in the concentration of 10 µM, pyrrolidinedithio-
carbamate (PDTC) in 100 µM, bisindolylmaleimide in 0.5 µM. Cerebral endothelial cells 
(CECs) isolated from brain cortical microvessels were cultured in DMEM supplemented with 
10% FCS. CECs grown in the presence of endothelial cell growth factor-α and its cofactor 
heparin (100 µg/ml) exhibit epithelial-like morphology (type I), while in the absence of them 
CECs have elongated spindle-like shape (type II) which is accompanied by actin filament 
reorganization. TGF-β (1 ng/ml) was added to the cell culture medium for 48 h.  
 
3.3. Plasminogen Activator Activity Determination by Zymography 
Epithelial cells were homogenized on ice in a buffer containing 20 mM Tris (pH=7.4), 150 
mM NaCl, and 0.5% Triton X-100. Homogenates were centrifuged at 10,000 g for 5 min and 
equal amounts of protein (25 µg) or equal volumes (25 µl) of culture medium were subjected 
to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under non-
reducing conditions. After the electrophoresis the gels were washed in 20 mM Tris (pH=7.4) 
2.5% Triton X-100 three times for 20 min to remove SDS and then in tridistilled water three 
times for 10 min. The gels were layered on agarose gel containing 2% casein and 5 µg/ml 
plasminogen and incubated at 37°C overnight in a wet chamber. Proteolytic activities were 
visualized as clear bands, uPA and tPA were identified on their molecular weights around 50 
kDa and 70 kDa, respectively. Densitometry was performed using the NIH Image software. 
 
3.4. Colorimetric Plasminogen Activator Assay 
PA activity was measured in culture medium (3, 6, 24 h) and cell lysates (24 h) in the absence 
or presence of uPA-inhibitor amiloride (1 mM). Plasminogen activation and the resulting 
plasmin hydrolysis was monitored by a colorimetric assay. Samples were incubated in 200 µl 
buffer containing 50 mM Tris (pH=7.4), plasminogen (0.3 mM), and D-Val-Leu-Lys p-
nitroanilide (0.3 mM). A standard curve was established using human uPA. The amount of p-
nitroaniline was detected by measuring the absorbance of the samples at 405 nm. 
 
3.5. Matrix Metalloproteinase Activity Measurement 
Cells were homogenized in a buffer containing 20 mM Tris (pH=7.4), 150 mM NaCl, 0.5% 
Triton X-100. Homogenates were centrifuged at 10,000 × g for 5 min. Protein samples were 
loaded on a 10 % acrylamide gel containing 2 mg/ml casein and subjected to SDS-PAGE 
under non-reducing conditions. Following electrophoresis the gels were washed 3 x 20 min in 
20 mM Tris (pH=7,4) 2.5% Triton X-100 to remove SDS followed by 3 x 10 min wash in 
tridistilled water. The gels were incubated in 20 mM Tris (pH = 7.4) and 5 mM CaCl2 at 37 
°C for 24 h. Proteolytic bands were visualized by staining the gels with Coomassie R-250. 
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3.6. Motility Assay 
Subconfluent lung epithelial cells, cultured in 6 cm Petri dishes, were wounded with a razor 
blade. Then the cells were washed three times with PBS and further incubated in the presence 
or absence of TNF-α, dexamethasone, or Y27632 for two days. Cells which had migrated in 
the denuded area from the wound edge were visualized by methylene blue staining.  
 
3.7. Occludin Immunostaining 
To characterize the morphology of TJ protein occludin, A549 cell cultures were washed in 
PBS and were fixed in ethanol for 30 min at 4 °C. After a blockade with 3% bovine serum 
albumin, the cells on coverslips were incubated with anti-occludin primary antibody (1:200 
dilution; Zymed Laboratories, USA) for 90 min, and washed three times in PBS. It was 
followed by incubation with secondary antibody Cy5-labelled anti-rabbit IgG (1:400 dilution) 
for 30 min. Preparations were mounted in Gel Mount (Biomeda, USA) and immunostaining 
was studied by a Nikon Eclipse 2000 fluorescent photomicroscope (Japan).  
 
3.8. Immunoprecipitation and Immunoblotting of Junctional Proteins 
A549 cells grown in Petri dishes were treated with 0.1-10.0 ng/ml TNF-α for 6 h. The cells 
were washed twice with PBS and lysed in 0.6 ml of a lysis buffer (20 mM Tris-Cl, 150 mM 
NaCl, 5 mM 2-mercaptoethanol, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% 
SDS). The lysates were centrifuged at 15,000 × g for 10 min, then precleared with protein G 
sepharose (GE Healthcare). Supernatants were incubated with anti-β-catenin antibodies (5 
µg) for 4 h at 4 °C, than the immunocomplexes were precipitated with protein G sepharose 
beads overnight at 4 °C. The precipitates were washed four times in the lysis buffer and 
boiled for 5 min in 100 µl of electrophoresis sample buffer to elute bound proteins. Protein 
samples were resolved on 9% polyacrylamide gels and transferred onto nitrocellulose 
membranes. Membranes were blocked in PBS containing 5% nonfat dry milk, incubated with 
primary antibodies for occludin, pan-cadherin (Santa Cruz), α- and β-catenin (Sigma) and 
fluorophore-labeled secondary antibodies (Jackson Laboratories). Immunoreaction was 
visualized by ECL plus chemiluminescence detection kit (GE Healthcare). 
 
3.9. Statistics 
All data are means ± standard error (SEM). Statistical analysis was performed using analysis 
of variance followed by Dunn’s test for densitometrical data, and by Student’s t-test for 
colorimetry PA data. P<0.05 values were considered significant changes. 
 
 
4. RESULTS 
 
4.1. Effect of Inflammatory Mediators on Plasminogen Activator Activity 
 
4.1.1. Concentration- and time-dependent induction of PA activity by TNF-α 
TNF-α induced PA activity has been measured both in the culture medium and the soluble 
fraction of cell lysates. In culture medium, strong activity at 50 kDa and weaker activity at 70 
kDa could be detected corresponding to uPA and tPA, respectively. Almost exclusively uPA 
was detected in soluble cellular fraction. Treatment of A549 cells with TNF-α for 6 h 
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induced significant, concentration-dependent activation of both uPA and tPA activity in the 
culture medium and an induction of the uPA activity in the soluble fraction of cell lysates. 
 
4.1.2. Effect of inhibitors on the induction of PA activity by TNF-α 
Administration of DXM (10 mM) did not change the PA activity in the culture medium and 
soluble fraction; however it could significantly reduce the TNF-α induced activation of both 
uPA and tPA. The effect of signal transduction inhibitors on TNF-α induced uPA activity has 
been also checked. Neither src-kinase inhibitor PP1 nor superoxide dismutase (SOD) could 
inhibit the TNF-α induced uPA activity. However, the Rho inhibitor Y27632 and MMP 
inhibitor phenanthroline were able to significantly inhibit the activation of uPA in A549 
human alveolar epithelial cells. Densitometrical analysis also proved that TNF-α induced 
uPA activation could be significantly inhibited by Y27632, phenanthroline, or DXM. 
 
4.1.3. Effect of bacterial LPS  and various cytokines on the PA activity 
Treatment with cytokines IL-1β, IL-2, IL-6, or bacterial LPS for 24 h resulted in changes in 
PA activity in A549 epithelial cells. Strong PA activity could be detected at 50 kDa (uPA) by 
zymography in the soluble fraction of cell lysates after IL-1β treatment, as well as weaker 
activity at around 70 kDa (tPA). LPS also increased uPA activity, whereas IL-2 and IL-6 did 
not produce significant changes. The effect of inflammatory mediators on PA activity was 
also estimated using colorimetric PA assay. IL-1β administration (10 ng/ml) caused about 9-
fold and 6-fold increases in total PA activity in culture medium at 3 h and 24 h, respectively, 
and similar increase in soluble cellular fraction at 24 h. Although IL-2 treatment (50 U/ml) 
for 24 h did not change total PA activity in cellular lysates, it induced significant increases in 
the activity in culture medium with a decreasing tendency between 3 h and 24 h. IL-6 
treatment (1 ng/ml) decreased PA activity in cell lysate, but not in culture medium. LPS 
incubation significantly elevated PA activity in culture medium between 3 and 24 h, however 
PA level in cell fraction was only slightly elevated after 24 h. IFN-γ (100 ng/ml) increased 
PA activity after 3 h, but not at 6 or 24 h, in culture medium, and after 24 h in cell lysates. 
Quantitative assays of PA activity were also performed in the absence or presence of uPA-
inhibitor amiloride (1 mM). The ratio of amiloride-sensitive (uPA) and amiloride-insensitive 
(tPA) activity was approximately 74-81% vs. 19-26% both in culture medium and cell 
lysates. Although slight time-dependent changes could be detected, this observation indicates 
that uPA is the predominant PA in cultured lung epithelial cells. Similar composition of PAs 
was seen in A549 epithelial cells treated with inflammatory mediators. 
 
4.2. MMP Activity in Epithelial and Endothelial Cells 
Metalloprotease zymography showed a proteolytic band at 72 kDa which corresponds to 
MMP-2 (gelatinase A). The MMP-2 activity was significantly stronger in the culture medium 
compared to that in the cell lysate. TNF-α induced activation of MMP-2 could be partially 
blocked by co-incubation with 10 nM DXM. Rho kinase inhibitor Y27632 also reduced TNF-
α induced activation of MMP-2. A faint proteolytic band corresponding to MMP-3 
(stromelysin 1) could be also detected at 40-45 kDa in the culture medium. MMP activity was 
also investigated in CECs and only MMP-2 activity could be detected in type I cells with 
epithelial characteristics, whereas strong MMP-3 activity was also seen in type II cells.   
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4.3. Migration Potential of Epithelial Cells  
After wounding the subconfluent lung epithelial cell layer with a razor blade, A549 cells 
moved from the wound edge into the denuded area. A549 cells migrate further from the 
wound edge in the presence of 5.0 ng/ml TNF-α. This effect could be reduced to the control 
level by DXM and Y27632. DXM and Y27632 alone did not influence the migration of cells. 
 
4.4. Integrity of Epithelial Cellular Barrier  
TNF-α treatment led to a relocalisation of TJ transmembrane protein occludin, although the 
expression of occludin did not change. TNF-α treatment dose-dependently decreased β-
catenin expression, whereas cadherin and α-catenin expression did not change. However, 
immunoprecipitation study with β-catenin antibody detected reduced amounts of cadherin 
and α-catenin in the β-catenin immunoprecipitates at higher TNF-α dose. This reduction may 
reflect recruitment of these proteins into insoluble membrane complexes. 
 
 
5. DISCUSSION 
 
The present study strengthens the views that cytokines promote fibrinolysis in alveolar 
epithelium and contribute to pathogenesis and repair of lung injury. New observations of the 
thesis have been discussed. 
 
5.1. Cytokines in the Induction of Proteolytic Enzymes in the Airways 
• It has been demonstrated that TNF-α strongly enhances the expression and release of 
uPA and tPA in human lung epithelial cells and DXM can inhibit these changes.  
• Our data support the views that bacterial LPS and cytokines IL-1β, IL-2, and IFN-γ 
can regulate the production and synthesis of PAs in alveolar epithelial cells.  
• It has been proved that uPA is responsible for approximately 75-80% of total PA 
activity in lung epithelial cells. 
• The role of Rho kinase-dependent mechanisms in the regulation of cytokine-induced 
activation of uPA in alveolar epithelial cells has been established in the present study. 
 
5.1.1. Effects of TNF-α and other inflammatory mediators on PA activity 
Cytokines and bacterial LPS were able to induce significant PA activity. TNF-α and IL-1β 
proved to be the strongest, time- and dose-dependent PA inducers in cell lysates and 
supernatants of alveolar A549 cells. IL-1β produced greater increase in PA activity in cell 
lysate, whereas TNF-α did it in supernatant. These data are in accordance with a previous 
study indicating that inflammatory mediators including LPS and IFN-γ had much lower 
capacity than IL-1β and TNF-α to cause an up-regulation of PA activity in pulmonary 
epithelial cells after 24 h. The effect of IL-1β on increased cell-surface plasmin generation is 
mediated in part by increased expression of uPAR which can be prevented by protein kinase 
C (PKC) inhibitors. Increased uPA levels in the supernatant of IL-1β stimulated epithelial 
cells indicated activation of fibrinolysis through plasmin system and resulted in quicker and 
more efficient alveolar epithelial repair. Upregulation may be caused by accumulation of 
newly synthesized uPA since TNF-α is able to induce rapid accumulation of uPA mRNA. 
It has been confirmed that the majority of total PA activity is amiloride-sensitive in A549 
cells. Our observation supports a predominant role for uPA in the proteolytic activity of 
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alveolar epithelial cells. Amiloride was shown to completely inhibit uPA in control and 
stimulated rat alveolar epithelial cells, while it did have no effect on tPA. 
 
5.1.2. Cytokine-induced signalling and PA activity 
Signal transduction pathways regulating epithelial proteolytic activity in response to 
inflammatory stimuli have been investigated and a role for Rho-dependent mechanisms in the 
regulation has been revealed. TNF-α and LPS induced increase in PA activity could be 
prevented by Y27632, a specific inhibitor of Rho kinase in alveolar epithelial cells. Y27632 
proved to be effective in a murine model of intravenous LPS-induced acute lung injury; it 
attenuated lung oedema, neutrophil emigration, and cytoskeletal rearrangement of pulmonary 
endothelial cells. In contrast to the in vitro observations, inhaled nebulized LPS inhibited PA 
activity and increased PAI-1 production in BAL fluid of healthy human volunteers. 
The role of Rho-associated protein kinases in mediating the effect of TNF-α is supported by 
the finding that down-regulation of Rho signalling by coexpression of dominant-negative 
Rho mutants (i.e RhoA, RhoB and Rac) impairs TNF-α driven E-selectin gene expression. 
Recent results indicate that the Rho family of small GTP-binding proteins plays an important 
role in the expression of NF-κB-dependent genes. However, in our experiments inhibition of 
NF-κB by PDTC did not inhibit the TNF-α induced activation of uPA, which suggests that 
TNF-α may also exert its effects through alternative signaling pathways. Furthermore, TNF-
α is able to induce a rapid, sustained increase in p38 and extracellular signal-regulated kinase 
1/2 (ERK1/2) activity in pulmonary endothelial cells which can be inhibited by Y-27632 
indicating that Rho acts upstream of mitogen-activated protein kinases in signalling. 
However, our results using the ERK inhibitor U0126 show that this mechanism is not 
involved in the regulation of uPA activity in lung epithelial cells.  
It has been shown that IL-1β induced transcriptional activation of the uPAR gene involves 
PKC-dependent mechanisms. The role of PKC in PA synthesis is well-known; treatment with 
phorbol myristate acetate, a PKC activator, caused time- and dose-dependent up-regulation of 
uPA synthesis by alveolar epithelial cells. However, we could not detect inhibition of  TNF-
α-induced uPA activation by the src-kinase inhibitor PP-1 and PKC inhibitor 
bisindolylmaleimide in A549 cells. Interestingly, PP-1 enhanced the TNF-α-induced uPA 
activation, which could be explained by the inhibitory effect of PP-1 on PAI-1 gene 
expression. Glucocorticoids have also been shown to suppress uPA activity probably due to 
interactions between the glucocorticoid receptor and another transcriptional activating system 
such as AP-1 and NF-κB. Since SOD did not affect TNF-α-induced uPA activation in our 
study, increased production of reactive oxygen species probably does not play significant role 
in this phenomenon. It is noteworthy that the MMP inhibitor phenanthroline inhibited uPA 
activity by 30% which could reflect a close connection between MMPs and PA system. 
 
5.1.3. Role of PA activity in the pathogenesis of pulmonary diseases 
Increased proteolytic activity can be seen in the lung in chronic inflammation. A recent 
Canadian study detected an association between allelic variants of human uPA gene PLAU 
located on 10q24 and asthma phenotype and confirmed that uPA might act as a regulator of 
asthma susceptibility. At the cellular level, an increase in pericellular proteolysis may release 
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chemotactic mediators and favor adhesion and migration of eosinophils, fibroblasts, and 
smooth muscle cells through the ECM in the lung tissue. 
Mechanical stimulation up-regulated the gene expression of uPA, tPA, and PAI-1; it 
increased uPA levels and uPA-dependent plasmin generation in cultured bronchial epithelial 
cells. Similar increase in epithelial uPA activity was seen in airway tissue samples of patients 
died in status asthmaticus. Local fibrinolytic activity of the lung tissue during inflammation 
might differ from the changes in BAL fluid. Intense PA activity was localized to areas of 
lung injury by in situ zymography after exposure to bleomycin in mice while the PA activity 
within lavage fluid was supressed. On the other hand, inhalation of exogenous uPA 
significantly reduced subepithelial fibrosis, decreased AHR, up-regulated plasmin activity in 
BAL fluid, and reduced airway remodelling in a murine model of chronic asthma. 
BPD was associated with higher concentrations of IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-γ 
and lower concentrations of IL-17. The pro-inflammatory cytokines, IL-1β and IL-6 and 
mediators which reflect neutrophil recruitment and activation, including soluble intercellular 
adhesion molecule, IL-8 and neutrophil elastase, were increased in BAL fluid obtained from 
infants who developed CLD. Fibroblast proliferation and components of the ECM, including 
collagen and fibronectin, are markedly increased in the lungs of infants who die from CLD of 
prematurity. Fibrosis is thought to be mediated by the pro-fibrotic cytokines including TGF-β 
and both active and total TGF-β were increased in BAL fluid. 
 
5.2. Regulation of Matrix Metalloproteinases in Alveolar Epithelial Cells 
• TNF-α induced regulation of MMP-2 has been shown in lung epithelial cells. 
• Treatment with DXM or Rho kinase inhibitor can prevent MMP-2 induction by TNF-
α.  
 
5.2.1. Effect of TNF-α and other cytokines on MMP induction 
We have investigated MMP activity in epithelial and endothelial cells and demonstrated 
strong TNF-α induced regulation of MMP-2 in alveolar epithelial cells. An induction of 
MMP expression by inflammatory mediators has been reported recently, but the mechanisms 
of inhibition was not presented. MMPs are known to degrade the ECM, basal membrane 
components, and are involved in the regulation of TJ proteins, such as occludin. Similar data 
have been obtained in a study showing that MMP-9 is induced by TNF-α in pulmonary 
microvascular endothelial cells. Fibroblast migration, proliferation, and MMP production 
were also shown to be regulated by IL-1β and TNF-α. The proinflammatory cytokines IL-1, 
IL-6, and TNF-α were shown to up-regulate MMPs both in vitro and in vivo. IL-1β is 
produced in a biologically inactive form and can be activated by cleavage with MMP9.  
 
5.2.2. MMPs in signalling and pulmonary diseases 
In this study, we provide evidence that DXM is able to reduce the activation of MMP-2. This 
finding is in line with previous results demonstrating that DXM inhibits the irradiation-
induced increase in MMP-2 in lung epithelial cells. An explanation could be that MMP-2 
gene contains putative binding sites for a variety of transcription factors which are regulated 
by glucocorticoids. In contrast, neutrophil MMP-9 activity in the BAL fluid was poorly 
inhibited by glucocorticoids. The role of Rho in the regulation of MMP-2 is less well 
understood. It has been shown that Rac1, one member of Rho-related small GTPases, is a 
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mediator of MMP-2 activation in fibrosarcoma cells. Our results suggest that Rho may be at 
least partially involved in te regulation of MMP-2 in lung epithelial cells. 
MMPs have been reported to play a critical role in the pathogenesis of acute and chronic lung 
diseases and in airway wall remodelling in chronic inflammatory processes of the respiratory 
system. In the lung, MMP-2 is preferentially secreted from fibroblasts and airway epithelial 
cells, and MMP-9 is preferentially expressed by inflammatory cells. Previous studies 
demonstrated that type IV collagen and MMP-2 showed co-localization in disrupted epithelial 
basement membrane. Furthermore, an increase in MMP-2 activity has been reported in 
epithelial lining fluid obtained from patients with acute RDS. 
Expression of MMP1, MMP2, MMP3, MMP8, and MMP9 has been associated with asthma. 
Increase in MMP9 activity in the subepithelial basement membrane was accompanied by 
higher TGF-β level. These studies suggest that in patients with severe asthma, neutrophils 
play a key role in lung remodelling because they express both MMP9 and TGF-β, which are 
involved in breakdown and repair of tissue, respectively. The amount of MMP2 at birth 
successfully predicted the outcome of BPD in preterm infants and birth weight was 
significantly correlated with amount of MMP2. The levels of MMP2, MMP8, MMP9 and 
TIMP-2 are elevated in tracheal aspirate from preterm infants with RDS. ECM components, 
including collagen and fibronectin, are increased in the lungs of infants who die from CLD. 
 
5.3. Migration Potential of Tumor Necrosis Factor-α Induced Epithelial Cells  
• The present study has demonstrated that TNF-α treatment increases the migration 
potential of wounded alveolar epithelial cells. 
• The inhibition of epithelial cell migration by dexamethasone or Rho inhibitor Y27632 
can be partly explained by the reduced protease activity. 
Cell migration is a highly integrated, multi-step process that plays an important role in the 
progression of various diseases including cancer. An increased proteolytic activity is often 
associated with an increased migratory potential mainly due to ECM degradation or 
proteolysis of cell surface molecules regulating cell-cell interactions. uPA facilitates cell 
migration by localizing proteolysis on the cell surface and by inducing intracellular signalling 
pathways. The role of uPA in human bronchial epithelial cell migration was confirmed when 
a monoclonal antibody raised against uPA showed 70% reduction in cell velocity.  
It was also observed that uPA was only detected in migrating cells at the wound edges and 
located at crucial sites for cell/ECM interactions. The action of uPA in the migration of 
human bronchial epithelial cells is mediated by the generation of plasmin, which in turn 
activates MMP-9, thus making cell migration possible. A significant dose-dependent increase 
was observed in cell migration velocity after treatment with plasmin or MMP-9. Moreover, 
addition of exogenous plasmin led to a twofold increase of activated MMP-9 in migrating 
cells, while the addition of uPA antibody led to an inhibition. It has been also known that Rho 
family GTPases regulate actin cytoskeleton, cell adhesion, and play an important role in cell 
polarisation and directional migration. 
 
5.4. Tumor Necrosis Factor-α and the Damage to Pulmonary Alveolocapillary Barrier 
• TNF-α-induced damage to the epithelial barrier integrity has been demonstrated in the 
present study. 
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• It has been revealed that relocalisation of occludin, decreased β-catenin expression, 
and modified recruitment of the proteins in adherens junction can contribute to the 
mechanism of barrier injury. 
The structural changes of epithelial barrier may well correspond to the increased permeability 
seen in in vivo and in vitro studies. In a rat model of pneumonia, histologic evidence of 
alveolar epithelial injury was seen 24 h after intratracheal instillation of bacteria. This 
increase was inhibited either by anti-TNF-α neutralizing antibody or by amiloride, an 
inhibitor of uPA. TNF-α (5 µg) instilled in normal rats could also increase alveolar liquid 
clearance by similar degree. In another study, LPS injection (2 mg/kg) resulted in leakage of 
FITC-dextran from blood into BAL fluid in endotoxaemic mice. This decrease in barrier 
function was associated with up-regulation of inducible nitric oxide synthase expression and 
NF-κB, and decreased expression of the TJ proteins ZO-1, ZO-2, ZO-3, and occludin in lung 
after the injection of mice with LPS. Release of TNF-α during pneumonia or peritonitis 
increases the transport capacity of the alveolar epithelium. Increased uPA expression can also 
enhance paracellular permeability across epithelial monolayers after asbestos treatment. 
Plasma proteins, including fibrinogen, will cross the altered lung epithelium and form fibrin 
in the distal airways. Alveolar epithelial cells express significant amounts of uPA that 
activates plasmin and leads to increased fibrin degradation. 
TNF-α can also induce barrier dysfunction in endothelium of the pulmonary vessels. TNF-α 
(1,000 U/ml) increased albumin permeability in bovine pulmonary artery endothelial cell 
monolayers, induced pulmonary endothelial F-actin depolymerization, intercellular gap 
formation, and barrier dysfunction. TNF-α activates PKC-α, then stabilization of actin fibers 
affects junctional proteins and altered cell-cell adherence results in the permeability response. 
The family of zinc- and calcium-dependent MMPs play an important role in remodelling of 
the airways in disease. Apical MMP9 significantly decreases immunostaining of TJ proteins 
and transepithelial electrical resistance in a model of well-differentiated human airway 
epithelia. MMP9 exerts its effects on the epithelium by cleaving one or more components of 
cell-cell junctions. Due to disruption of barrier function viruses gained access to the epithelial 
basolateral surface, which could increase infection efficiency.  
 
 
6. CONCLUSIONS 
 
The new observations of the present study indicate that cytokines promote fibrinolysis in 
alveolar epithelium and contribute to pathogenesis and repair of lung injury. It has been 
demonstrated that TNF-α enhances the expression and release of uPA, tPA and MMP-2 in 
human lung epithelial cells. TNF-α-induced proteolytic activity can be inhibited by DXM and 
Rho-kinase inhibitors. TNF-α induced structural change in the barrier integrity of epithelial 
monolayers was also demonstrated in alveolar epithelial cells. 
 
Data obtained on in vitro models may contribute to detection of the signal transduction 
pathways regulating epithelial proteolytic activity in response to inflammatory stimuli and to 
identification of potential therapeutic target molecules. 
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